Strategic Vision: A Global Pharma Company
Other Markets
EU5
Australia
South Africa
Germany: EUR 8.4 mn sales in Q4 FY22
Tempil ® & Mens Health Portfolio have contributed to double-digit YoY growth
4th largest generics player¹
Growth of 30% against industry growth of 7.5%¹
4th largest Rx generics player2; Market leader in CVS space
Emerging markets
Developed
•
ZAR 426 mn sales in Q4 FY22
Brazil
Mexico
BRL 64 mn sales in Q4 FY22 (up 8% YoY);
In our reference market, MedQuimica ranks #6 in units and #14 in Values
MXN 183 mn sales in Q4 FY22; (growth of 19% YoY)
Market Leader in Ophthalmology (#2 in units and #5 in values) with a national footprint
API + Global
Institutional
1. IQVIA Midas Sales Audit MAT Dec-21
API revenues declined 14% YoY in Q4 FY22
Continued leadership in anti-TB Institutional business
2. IQVIA Feb-22
9
LUPINView entire presentation